- Home
- GWRS vs TNGX Comparison
GWRS vs TNGX Comparison
Compare GWRS & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GWRS
- TNGX
- Stock Information
- Founded
- GWRS 2003
- TNGX 2014
- Country
- GWRS United States
- TNGX United States
- Employees
- GWRS N/A
- TNGX N/A
- Industry
- GWRS Water Supply
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- GWRS Utilities
- TNGX Health Care
- Exchange
- GWRS Nasdaq
- TNGX Nasdaq
- Market Cap
- GWRS 286.0M
- TNGX 248.2M
- IPO Year
- GWRS 2010
- TNGX N/A
- Fundamental
- Price
- GWRS $10.00
- TNGX $2.54
- Analyst Decision
- GWRS
- TNGX Strong Buy
- Analyst Count
- GWRS 0
- TNGX 6
- Target Price
- GWRS N/A
- TNGX $12.20
- AVG Volume (30 Days)
- GWRS 36.8K
- TNGX 3.7M
- Earning Date
- GWRS 05-14-2025
- TNGX 05-12-2025
- Dividend Yield
- GWRS 3.03%
- TNGX N/A
- EPS Growth
- GWRS N/A
- TNGX N/A
- EPS
- GWRS 0.23
- TNGX N/A
- Revenue
- GWRS $53,539,000.00
- TNGX $40,990,000.00
- Revenue This Year
- GWRS $7.63
- TNGX N/A
- Revenue Next Year
- GWRS $5.58
- TNGX N/A
- P/E Ratio
- GWRS $43.43
- TNGX N/A
- Revenue Growth
- GWRS 3.94
- TNGX 10.09
- 52 Week Low
- GWRS $9.37
- TNGX $1.03
- 52 Week High
- GWRS $13.98
- TNGX $12.02
- Technical
- Relative Strength Index (RSI)
- GWRS 41.88
- TNGX 68.03
- Support Level
- GWRS $9.95
- TNGX $1.93
- Resistance Level
- GWRS $10.22
- TNGX $2.67
- Average True Range (ATR)
- GWRS 0.23
- TNGX 0.42
- MACD
- GWRS -0.02
- TNGX 0.09
- Stochastic Oscillator
- GWRS 8.58
- TNGX 73.71
About GWRS Global Water Resources Inc.
Global Water Resources Inc operates as a water resources management company that owns, operates, and manages water, wastewater, and recycled water utilities in strategically located communities, principally in metropolitan Phoenix, Arizona. It operates within the State of Arizona.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.